Complete Round 1 data (baseline and 12-month follow-up) for HPV FOCAL, a randomized trial establishing the efficacy of HPV DNA testing with cytology triage as a primary screen for cervical cancer are presented. Women were randomized to one of three arms: Control arm -Baseline liquid-based cytology (LBC) with ASCUS results triaged with HPV testing; Intervention and Safety arms -Baseline HPV with LBC triage for HPV positives. Results are presented for 15,744 women allocated to the HPV (intervention and safety combined) and 9,408 to the control arms. For all age cohorts, the CIN31 detection rate was higher in the HPV (7.5/1,000; 95%CI: 6.2, 8.9) compared to the control arm (4.6/1,000; 95%CI: 3.4, 6.2). The CIN21 detection rates were also significantly higher in the HPV (16.5/1,000; 95%CI: 14.6, 18.6) vs. the control arm (10.1/1,000; 95%CI: 8.3, 12.4). In women 35 years, the overall detection rates for CIN21 and CIN31 were higher in the HPV vs. the control arm (CIN21:10.0/1,000 vs. 5.2/1,000; CIN31: 4.2/1,000 vs. 2.2/1,000 respectively, with a statistically significant difference for CIN21). HPV testing detected significantly more CIN21 in women 25-29 compared to LBC (63.7/1,000; 95%CI: 51.9, 78.0 vs. 32.4/1,000; 95%CI: 22.3, 46.8). HPV testing resulted in significantly higher colposcopy referral rates for all age cohorts (HPV: 58.9/1,000; 95%CI: 55.4, 62.7 vs. control: 30.9/1,000; 95%CI: 27.6, 34.6). At completion of Round 1 HPV-based cervical cancer screening in a population-based program resulted in greater CIN21 detection of across all age cohorts compared to LBC screening.
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Background
Globally, cervical cancer remains a leading cause of cancer for women, and each year over half a million women are diagnosed with this preventable form of cancer. 1 In lowincome countries, cervical cancer remains one of the most common cancers in women, 1 but in high-income countries, rates of cervical cancer have significantly decreased during the past decades, due in large part to the implementation of Pap smear-based cervical cancer screening programs. 2, 3 With the established understanding of the human papillomavirus (HPV) as the necessary cause of cervical cancer, 4, 5 the development of highly effective multivalent HPV vaccines [6] [7] [8] to prevent infection with HPV and the molecular tests to detect cervical HPV infections, 9,10 jurisdictions need to re-examine fundamental aspects of their cervical cancer prevention and screening programs. In particular, given the natural history of cervical cancer, programs should review the type of screening test used, the ages at which to start and stop screening and intervals between cervical cancer screens to ensure that women are offered the most effective screening intervention and that harms are minimized.
Over the past decade, evidence from randomized trials has emerged demonstrating that molecular HPV-based screening offers significantly improved sensitivity and negative predictive value compared to Pap (cytology) screening as the primary test for prevention of cervical cancer. [11] [12] [13] However, while the previous trials have been well designed, they had some limitations, including the use of combined cytology and HPV testing in the experimental (HPV) arm; (14) (15) (16) the use of conventional cytology instead of Liquid-Based Cytology (LBC) [15] [16] [17] or methodological limitations, such as ongoing opportunistic screening during the trial. 18 In addition, data on the optimal age to begin HPV screening and the interval between screens remain limited. Trials that are designed to minimize these limitations and include a rigorous examination of the impact of HPV-based screening in women aged 25-65, as well as an extended screening interval, will make important contributions in defining optimal guidance for implementation of HPV-based screening.
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In our study, we present the final Round 1 results of the HPV testing for Cervical Cancer Screening trial (HPV FOCAL), 20, 21 a Canadian randomized clinical trial (RCT) comparing the efficacy of HPV testing vs. LBC for primary cervical cancer screening on rates of cervical intraepithelial neoplasia (CIN) in women 48 months after the baseline screen.
Methods

Trial background
HPV FOCAL is a population-based RCT (ISRCTN79347302) comparing the efficacy of primary high-risk HPV DNA testing (HPV testing) with reflex LBC for HPV positive women vs. LBC with reflex HPV testing in women with ASCUS (atypical squamous cells undetermined significance) on CIN grade 3 or worse (CIN31) rates at the 48-month exit screen. The primary trial objective is to establish the efficacy of HPV testing with reflex LBC as a primary screen for cervical cancer. Details of the trial methodology have been published previously. 20, 21 Briefly, over 25,000 women between the ages of 25 and 65 who were participants in the Cervical Cancer Screening Program (CCSP) in British Columbia (BC), Canada and were due for cervical cancer screening were randomized into the trial. Every woman in British Columbia who has ever received a cervical screen is included in the CCSP.
Eligible women were identified by the CCSP and sent trial invitation letters through collaborating family physicians (CFPs). If no response was received from the invited women, a reminder invite was sent by CFPs 4 weeks later. Women were enrolled through two processes. They could respond to the invite letter and call the study-center for more information and instructions. In addition, CFPs also enrolled women from the screening program who met eligibility criteria and presented for screening at their clinics but who had not previously respond to the invite letter. Women who consented to participate were randomly assigned, to one of three trial arms ( Fig. 1 Thereafter, women were randomized 1:1 into the Control and Intervention arms.
For women who tested positive on their baseline screen (i.e., HPV or LBC), a specific triage protocol was followed in Round 1. to colposcopy and managed based on these results. If baseline LBC was ASCUS, reflex testing with HPV was conducted, and if HPV positive, women were referred to colposcopy and managed based on these results. If ASCUS and reflex HPV negative, women were recalled for subsequent LBC testing in 12 months and if ASCUS at the 12-month subsequent screen, women were referred to colposcopy and managed based on these results. If cytology negative (NILM) at this 12-month subsequent screen, women were then recalled for their 24-month LBC screen.
Some changes in the trial protocol since initial methods publication include: closure of the safety arm to further recruitment January 1, 2011(as described earlier) and extension of recall for subsequent screen from 6 to 12 months in March 2010. No women in the control arm and 58 women in the HPV arm had only 6-month subsequent screens, so for purposes of this evaluation, results for the 6-and 12-month subsequent screen are combined.
Screening Tests
All HPV and LBC specimens for the trial (and for the province) were read at the single provincial cytology laboratory within the Lower Mainland Laboratories in Vancouver, BC. Cervical samples were obtained in ThinPrep V R (PreservCyt V R , Hologic, Bedford MA). For the intervention and safety arms, an aliquot for HPV primary screening was removed from the sample prior to LBC processing; for the control arm, aliquots for those requiring HPV testing were removed after LBC processing. LBC slides were prepared via automated processing with the ThinPrep V R 2000 (Hologic), but were evaluated and read manually by program certified screen technologists. HPV testing was performed with the Qiagen hc2 
Quality Assurance
All cytology specimens were reviewed at the central provincial laboratory that is CAP (College of American Pathologists) accredited. This laboratory conducts all cytology for the province, and engages in the routine quality assurance expected of an accredited laboratory including 10% rescreen of negative cervical cytology samples and 5-year retrospective review of previously reported negative cases when a new high-grade abnormality is detected. Over 93% of the colposcopy procedures in the trial were conducted at two specific centers and these histology specimens were interpreted by trial specific pathologists blinded to the screen results that referred the woman to colposcopy. Pathology laboratories where histology was reviewed are affiliated with the BC Cancer Agency and trial pathologists conduct the large volume of cervical histopathology in the province.
For purposes of this trial, colposcopists were instructed to obtain biopsies on all trial participants; however, there are some participants for whom biopsy was not obtained (i.e., woman was pregnant or sample was insufficient). To better reflect real-world management, trial colposcopists were not blinded to screening (i.e., HPV or cytology) results. However, as discussed earlier histopathological assessments were conducted blind. The majority of colposcopy care for HPV FOCAL was provided at two of the highest volume colposcopy clinics in the province, and colposcopy procedures and management were standardized.
Trial Design Considerations
Having commenced in 1960, the BC CCSP is a long-standing provincial cervical cancer program. The screening history of every woman in the province is maintained in one centralized database, and all cervical screens are processed at a single provincial cytology laboratory. The HPV FOCAL trial is embedded within the CCSP, and thus was able to collaborate with the CCSP to minimize opportunistic screening of trial participants and to ensure standardized colposcopy follow-up procedures to enhance protocol compliance and validity of trial results. To minimize opportunistic screening on trial participants, the laboratory and HPV FOCAL study databases were linked so that any non-trial screens (NTS) on study participants were flagged upon receipt at the provincial cytology laboratory. For every NTS received, the HPV FOCAL trial staff contacted the ordering clinician to determine if the NTS required processing (i.e., for clinical indications) or was taken in error and did not need to be processed. 22 To enhance colposcopy compliance and standardization, all trial participants were referred to trial specific colposcopy clinics, where clinicians used standardized algorithms for HPV FOCAL participants. As a result, colposcopy adherence to recommendations in the trial has consistently been 95% based on ongoing trial quality assurance reviews
Statistical Analysis
The overall primary trial outcome for HPV FOCAL is the cumulative detection rate of greater than or equal to CIN3 in the intervention arm compared to the control arm at 48 months. For the purposes of this analysis, the main objective is to compare baseline, subsequent 12-month and overall detection rates for greater than or equal to CIN grade 2 (CIN21) and CIN31 at the completion of Round 1 of screening. "Round 1" includes valid results from trial participants, from baseline up to and including the 12-month subsequent screen. "Baseline screen" represents results from the initial testing including the triage results for that test. 
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"Subsequent screen" denotes results for women who required and received 12-month follow-up testing. "Round 1 overall screen" refers to the combined results from baseline and subsequent screens. For the current analysis results from the intervention and safety arms were combined (HPV arm) up to the end of Round 1 (as trial testing and management up to the end of Round 1 for women in the safety and intervention arms is identical). Detection rates were calculated by dividing the number of screen-detected cervical lesions by the total number of women tested. Colposcopy referral rates were calculated in a similar fashion, by dividing the number of women referred to colposcopy by the total number of women tested. Positive predictive value was calculated by dividing the number of women with screen detected cervical lesions (true positive screens) by the overall number of positive screens. Confidence intervals for rates were calculated using Wilson's method. v 2 testing was used to compare categorical demographic data. All analyses were performed using SAS/STAT software version 9.3 (SAS Institute, Cary, NC).
HPV FOCAL is funded by the Canadian Institutes of Health Research (MCT82072). Ethics approval was received from the BC Cancer Agency branch of the University of British Columbia Clinical Research Ethics Board (H06-04032).
Results
Trial recruitment commenced in January 2008 and was completed in May 2012. By May 2012, there were over 76,000 potentially eligible participants identified in the CCSP who were patients of over 200 CFPs. From the two enrollment methods (through the study call center process or through CFPs), 25,223 women were randomized into HPV FOCAL. A total of 51,199 women were excluded from the trial; 43,645 women did not respond to the invite; 5,644 formally declined and 1,910 did not meet inclusion criteria. Of the 25,223 women in the provincial screening program randomized into the trial, 12,248 were recruited through the invite process and 12,975 were identified by a CFP. There were 9,457 and 15,766 women randomized to the control and HPV arms, respectively (Fig. 2) .
A total of 25,223 women were randomized into HPV FOCAL, and data are presented for 25,152 (99.7%) participants with valid baseline results who completed Round 1 of the trial (Fig. 3 ). There were 15,744 women in the combined HPV arm with valid baseline results, and 9,408 women in the control arm with valid baseline results. There were no differences in the distributions of sociodemographic and lifestyle characteristics, including age, educational level, ethnicity, lifetime sexual partners and smoking history, between the HPV and the control arms (Table 1) . Over 80% of trial participants had at least some post high-school education and the majority had fewer than 10 lifetime sexual partners. At some point in their lives, 36% of trial participants have smoked.
Of the 15,744 women with valid baseline results in the HPV arm, 8.2% were HPV positive at baseline screen (Fig. 3) . Of the HPV positive women, 62.7% were negative or NILM (negative for intraepithelial lesions or malignancy) on reflex cytology testing, and were referred for a subsequent screen at 12 months. In the subsequent screen at 12 months, 44% of the initially baseline HPV positive/cytology negative (NILM) women were both HPV and cytology negative (NILM). Of the 9,408 women with valid baseline results in the control arm, 96.4% were cytology negative (NILM) at initial screen. Of the ASCUS positive women in the control arm who received reflex HPV testing, 61.8% were HPV negative and were referred for a subsequent screen at 12 months. At this subsequent cytology screen 12 months later, 79.2% of the baseline ASCUS/HPV negative women were cytology negative (NILM).
Although the baseline screen was similar between HPV and control arms for detection of both CIN21 and CIN31, it is noteworthy that after the subsequent screen, the detection rates for both CIN21 and CIN31 were much greater in the HPV than the control arm (Table 2) . At the end of Round 1, the CIN31 detection rate was higher in the HPV arm (7.5/1,000; 95%CI: 6.2, 8.9) compared to the control arm (4.6/1,000; 95%CI: 3.4, 6.2) for all age cohorts. Similarly, CIN21 detection rates were significantly higher in the HPV arm (16.5/1,000; 95%CI: 14.6, 18.6) vs. the control arm (10.1/ 1,000; 95%CI: 8.3, 12.4). In women 35 years, the overall detection rates for CIN21 and CIN31 were both higher in the HPV vs. the control arm (CIN21: 10.0/1,000 vs. 5.2/1,000; CIN31: 4.2/1,000 vs. 2.2/1,000, respectively). However, the difference in detection rates was only significant for CIN21 in women 35. In women 25-29, HPV detected significantly more CIN21 compared to LBC (control arm) (63.7/1,000; 95%CI: 51.9, 78.0 vs. 32.4/1,000; 95%CI: 22.3, 46.8) but this was not the case for CIN31.
For all age cohorts, Round 1 colposcopy referral rates were significantly higher in women who received HPV testing compared to women screened with LBC (HPV: 58.9/1,000; 95%CI: 55.4, 62.7 vs. Control: 30.9/1,000; 95%CI: 27.6, 34.6). For women 25-29, the respective colposcopy referral rates for HPV vs. control arm were 199.0/1,000 vs. 80.9/1,000. For women 35 years, the respective rates were 38.1/1,000 vs. 20.9/1,000 at the completion of Round 1. Across all age strata, use of HPV-based screening resulted in significantly higher colposcopy referral rates.
Discussion
HPV FOCAL is the first North American trial to compare cervical cancer screening modalities of primary HPV testing 
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and liquid-based cytology for the detection of precancerous lesions. The completed Round 1 screening results from HPV FOCAL found that screening using HPV in a provincial screening program with minimal opportunistic screening, standardized colposcopy follow-up and blinded histology assessment, resulted in greater detection of CIN21 and CIN31 across all age cohorts compared to screening with LBC. These findings have particular relevance and importance for the future of screening. 23, 24 HPV FOCAL was conducted in a setting with a structured CCSP, which includes a single screening registry; rigorous and standardized quality assurance for colposcopy and cytology; and one centralized laboratory. As evidence of the screening program's effectiveness, the age-standardized annual incidence rate of cervical cancer in British Columbia is 5.2 per 100,000 women, one of the lowest in the Western world. 25 HPV FOCAL was embedded in this highly efficient program. In addition, the trial has particular methodological strengths not evident in other randomized trials comparing HPV-based screening and cytology. Even with the trial methodological strengths and operating within this optimal organizational setting, the use of HPV as opposed to cytology as the primary screen for cervical cancer resulted in increased detection of precancerous lesions in the first round of screening. In the trial exit screen round 48 months after baseline screening, it will be determined whether women who received HPV-based screening will be less likely to have precancerous lesions compared to women who received cytology testing at baseline. In contrast to usual practice in the United States and other clinical trials in this field, HPV FOCAL did not offer cytology co-testing with HPV. Adding co-testing with cytology to HPV has been found to only slightly increase sensitivity for CIN21 whilst reducing overall specificity. 26 However, to leverage the added specificity of cytology, reflex cytology was applied to women who were HPV positive in the HPV arm, and followup decisions were based on the combined HPV and cytology results. This facilitated the identification of potentially transient HPV infections that did not result in dysplasia, with the intent of minimizing the number of unnecessary colposcopy procedures on women with HPV infections. 27 In most population-based studies, HPV prevalence is highest in younger women (<35 years) 28, 29 and most of those are a result of transient HPV infections that will clear without leading to any cervical lesions of consequence. 30 As such, there is uncertainty as to whether there is an advantage to offering HPV-based screening to women in these younger cohorts, as screening may result in increased false positive screens and unnecessary procedures, including colposcopy and treatment. To address this question, HPV FOCAL included women aged 25-34 in the trial to offer rigorous evaluation of the impact of HPV-based primary screening on detection, colposcopy rates and ultimately on prevention of cervical cancer in this age group. In this initial analysis, despite the use of reflex cytology to increase specificity of HPV screening, there was a significant increase in colposcopy referral rates in the HPV arm compared to the cytology arm across all age strata but particularly in women under 30, where the colposcopy referral rate was more than double in the HPV arm compared to cytology (199.0/1,000 vs. 80.9/ 1,000, p < 0.05). The 48-month exit round results will be particularly crucial to help direct and advise programs as to whether HPV-based screening has detected relevant lesions earlier in these younger age groups or whether it has detected extra lesions which are not clinically relevant and resulted in over diagnosis and over treatment of this group. It is plausible to assume, however, that ongoing HPV vaccination will lower the prevalence of HPV infection among women aged 25-34, which may obviate the concerns about the excessive number of colposcopy referrals for woman screened in this age group.
While HPV-based screening improves sensitivity and negative predictive values compared to cytology, HPV testing has poorer specificity. This can result in unintended harms to women who test falsely positive through an HPV-based screening program. However, there are significant opportunities to improve HPV reflex testing modalities; specifically with alternate technologies such as HPV mRNA, p16 and Ki67staining, genotype specific testing or HPV and/or host DNA methylation. 9, 31 These advanced molecular techniques may offer similar sensitivities and negative predictive values to HPV-based testing but could enhance specificity, which would ultimately minimize unnecessary procedures, permit streamlined referrals to colposcopy and reduce unintended harms of screening. As part of the trial protocol, HPV FOCAL mandated that dual cervical specimens were obtained and stored at the time of baseline screening on all 25,000 trial participants. These stored specimens will allow us to examine the diagnostic accuracy of alternate molecular tests in a prospective and blinded fashion and will allow definition of the potential impact of these alternate modalities on detection rates and precancerous lesions in the different trial arms and age strata. This uniquely positions the results of the HPV FOCAL trial to answer critical "next-step" questions that will be particularly valuable as the rapid development of molecular technology offers great promise for improved detection, but requires careful examination to ensure that any improvement in specificity is not at the cost of reduced sensitivity.
We anticipate that the 48-month results for HPV FOCAL will be available in the near future. Current Canadian screening guidelines continue to recommend cytology screening, so these findings will provide critical guidance on the impact of and potential for HPV-based primary screening for cervical cancer in screening programs. In our Round 1 data, we found that primary HPV screening detects significantly more CIN21 compared to cytology. The next phase is to determine whether the increased detection rate in Round 1 results in fewer lesions in the intervention arm, 48 months after baseline screening. It is noteworthy that in the control arm, the participants will have undergone two screens prior to exit (baseline screen and at 24 months) thus increasing the opportunity to detect relevant lesions in the control arm compared to the intervention arm, where participants underwent only one screening round before the 48-month exit screen. Therefore, the HPV FOCAL 48-month results will provide a conservative evidence base to judge the value of HPV testing relative to that of cytology in screening.
Cervical cancer screening is one of the most widely accessed preventive health interventions. Virtually all women of child-bearing age have undergone at least one screen during their lifetime in high-income countries and thus, any change in the screening paradigm will have an enormous population level and system impact. Round 1 results from HPV FOCAL confirm that, even in settings with optimal organizational structures and compared to liquid-based cytology, HPV primary screening detects a greater number of precancerous lesions. It is anticipated that the results from 48 months of screening will be very informative and provide critical policy direction regarding the impact of HPV primary screening. At the same time, numerous unanswered questions remain, including how best to optimize HPV-based triage; ongoing impact of primary HPV testing on colposcopy; ideal age to start HPV-based screening and defining strategies for integrating HPV testing in a vaccinated population. HPV FOCAL has created a structure that is uniquely poised to answer these relevant policy questions, and we anticipate the findings to be highly informative for jurisdictions worldwide in determining public health policy.
